ADMA Biologics, Inc. (NASDAQ: ADMA)

ADMA is a late stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons.

ADMA also operates ADMA BioCenters, an FDA-licensed source plasma collection facility which provides a portion of blood plasma for the manufacture of the Company’s lead product candidate RI-002.

Recent News